FDA’s History: Past, Present and Future
Presented To
University of California, Irvine
Graduate Degree Programs

Marlene Garcia Swider, PhD
Quality System Manager
Division of Pharmaceutical Quality Operations IV, OPQO, ORA, FDA
March 23, 2018
Acknowledgments

Information contained in these slides are all based on public information.

Thanks to:
Dr. William Martin, Director,
Pacific Southwest Food and Feed Laboratory, Office of Regulatory Affairs, FDA, for the designs and material included in History slides

and

Office of Regulatory Affairs for the information provided for Program Alignment slides.
U. S. Government:

- Judicial
- Legislative

Executive

President
Vice President

Cabinet
White House Staff
FDA is responsible for:

- protecting the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products, medical devices, our nation’s food supply, cosmetics, dietary supplements, and products that give off radiation
- regulating tobacco products
FDA History

Since 1906...

The Dining Room of “The Poison Squad”
Our Challenges

Scientific Breakthroughs

More Sophisticated Products

New Public Health Threats

International Commerce

Consumer Information
• FDA uses regulations and product standards as the "yardsticks" that define specific requirements manufacturers must follow to assure product safety and to provide accurate information to health professionals and consumers.

• FDA works with foreign governments to encourage the safety and quality of imported products by making sure that foreign standards are equivalent to those enforced by FDA.
• FDA has **authority** over regulated products in *Interstate Commerce*:
Origins
The FDA can trace its history back to the appointment of chemist Lewis Caleb Beck to the Agricultural Division in the Patent Office in 1848.

However, the nauseating condition of the meat-packing industry that Upton Sinclair captured in The Jungle was the final precipitating force behind both a meat inspection law and a comprehensive food and drug law.
FDA’s History (cont’)

FDA’s origins as a federal consumer protection agency began with the passage of the **1906 Pure Food and Drugs Act**. This law was the culmination of about 100 bills over a quarter-century that aimed to rein in long-standing, serious abuses in the consumer product marketplace.

*Early analysis for mold in Ketchup:*
Origins -1906

The passage of the 1906 Act was due in large part to the untiring scientific and political efforts of Harvey Washington Wiley, who at the time was chief chemist of the Bureau of Chemistry of the U.S. Department of Agriculture, FDA’s predecessor. The 1906 Act, which prohibited misbranded and adulterated food and drugs in interstate commerce, charged the Bureau of Chemistry to carry out its provisions. Eventually, the position of Chief Chemist of the Bureau of Chemistry evolved into that of the Commissioner of Food and Drugs.
Origins -1930’s

By the 1930s it was widely recognized that the Food and Drugs Act of 1906 was obsolete, but bitter disagreement arose as to what should replace it.

By 1937 most of the arguments had been resolved but Congressional action was stalled. Then came a shocking development--the deaths of more than 100 people after using a drug that was clearly unsafe.
1937:

New Hazards
New Laws
Origins -1938

The **1938 Food, Drug, and Cosmetic Act** tightened controls over drugs and food, included new consumer protection against unlawful cosmetics and medical devices, and enhanced the government’s ability to enforce the law.

*This law, as amended, is still in force today.*
Kevadon (or better known by its generic name, Thalidomide) was a widely used drug in the 1950s to support sleep and to treat nausea in pregnant women.
Origins -1960

Frances Oldham Kelsey, a medical officer at the Food and Drug Administration in Washington, who raised concerns about thalidomide before its effects were conclusively known.

For a critical 19-month period, she fastidiously blocked its approval while drug company officials maligned her as a bureaucratic nitpicker.
The *Kefauver-Harris Amendments of 1962*, which were inspired by the Thalidomide tragedy in Europe (and the FDA's vigilance that prevented the drug's marketing in the United States), strengthened the rules for drug safety and required manufacturers to prove their drugs' effectiveness.
Origins - 1970’s

1972 – 1973: Pacemaker failures reported

1975: Congressional Hearing - Dalkon Shield intrauterine device caused thousands of injuries.

Class I, II, and III Medical Devices defined based on degree of control necessary to be safe and effective.
The Medical Device Amendments of 1976 followed a U.S. Senate finding that faulty medical devices had caused 10,000 injuries, including 731 deaths. The law applied safety and effectiveness safeguards to new devices.
The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), signed into law on June 22, 2009, gives FDA authority to regulate the manufacture, distribution, and marketing of tobacco products. It puts in place specific restrictions on marketing tobacco products to children and gives FDA authority to take further actions to protect public health.
The Affordable Care Act explicitly states that manufacturers and authorized distributors must submit the following information concerning drug sample distribution to FDA:

(1) the identity and quantity of drug samples requested;
(2) the identity and quantity of drug samples distributed;
(3) the name, address, professional designation, and signature of any person who makes or signs for the request, and
(4) any other category of information determined appropriate by the Secretary.
The **FDA Food Safety Modernization Act (FSMA)**, the most sweeping reform of our food safety laws in more than 70 years, was signed into law by President Obama on January 4, 2011.

*It aims to ensure the U.S. food supply is safe by shifting the focus from responding to contamination to preventing it.*
The Food and Drug Administration Safety and Innovation Act (FDASIA), signed into law on July 9, 2012, expands the FDA’s authorities and strengthens the agency's ability to safeguard and advance public health by:

1) Giving the authority to collect user fees from industry to fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biological products;
2) Promoting innovation to speed patient access to safe and effective products;
3) Increasing stakeholder involvement in FDA processes; and
4) Enhancing the safety of the drug supply chain.
The Drug Quality and Security Act (DQSA), was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States. This will enhance FDA’s ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. The system will also improve detection and removal of potentially dangerous drugs from the drug supply chain to protect U.S. consumers. Additionally, the DSCSA directs FDA to establish national licensure standards for wholesale distributors and third-party logistics providers, and requires these entities report licensure and other information to FDA annually.
The 21st Century Cures Act (Cures Act), signed into law on December 13, 2016, is designed to help accelerate medical product development and bring new innovations and advances to patients who need them faster and more efficiently.

The law builds on FDA's ongoing work to incorporate the perspectives of patients into the development of drugs, biological products, and devices in FDA's decision-making process. Cures enhances our ability to modernize clinical trial designs and clinical outcome assessments, which will speed the development and review of novel medical products, including medical countermeasures.
Generic drug user fees make it possible for FDA and industry to continue to ensure that the American public has access to safe and high quality generic drugs and generic drug products.

The implementation of the **Generic Drug User Fee Amendments** (GDUFA) encompasses a wide range of activities that fall within the scope of regulating the generic drug industry. GDUFA was reauthorized on August 18, 2017 (GDUFA II), with provisions that went into effect October 1, 2017 and remain in effect through September 30, 2022.
FDA Guidance Documents

Guidance documents represent FDA's current thinking on a topic.

They do not create or confer any rights for or on any person and do not operate to bind FDA or the public.

You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations.
FOOD AND DRUG ADMINISTRATION
OFFICE OF THE COMMISSIONER

Commissioner of Food and Drugs
Scott Gottlieb, M.D.

Chief of Staff
Lauren Silvis J.D.

OFFICE OF
THE CHIEF COUNSEL

Chief Counsel
Rebecca (Breezy) K. Wood, J.D.
(DAA)

OFFICE OF
THE EXECUTIVE SECRETARIAT

Director
Marina M. Varasado
(DAB)

OFFICE OF
THE CHIEF SCIENTIST

Chief Scientist
RADM Denise Hilton (Acting)
(DAE)

OFFICE OF
COUNSELOR TO THE COMMISSIONER

Counselor to the Commissioner
Lawell J. Schiller, J.D.
(DAR)

OFFICE OF
EXTERNAL AFFAIRS

Associate Commissioner for External Affairs
John (Jack) Kalfantinos
(DAU)

OFFICE OF
LABORATORY SCIENCE AND SAFETY

Director
Sergio R. Pillai, Ph.D.
(DAZ)

OFFICE OF
WOMEN'S HEALTH

Assistant Commissioner
Mantha S. Henderson, M.D., M.P.
(DAS)

OFFICE OF
MINORITY HEALTH

Director
CAPT Richardson (Charlise)
Adams, Pharm.D.
(DAY)

OFFICE OF
REGULATORY SCIENCE AND INNOVATION

Director
Carol Lindsey, Ph.D.
(DAI)

OFFICE OF
COUNTERTERRORISM AND EMERGING THREATS

Assistant Commissioner
RADM Carleen Mathen (Acting)
(DAES)

OFFICE OF
SCIENTIFIC INTEGRITY

Director
George (Matthew) Warren, J.D.
(DAES)

OFFICE OF
SCIENTIFIC PROFESSIONAL DEVELOPMENT

Director
Leslie Wheelock
(DAES)

OFFICE OF
HEALTH INFORMATICS

Director
Elaine Johnson (Acting)
(DAES)

OFFICE OF
MEDIA AFFAIRS

Assistant Commissioner
Jennifer Rodriguez (Acting)
(DAUA)

OFFICE OF
COMMUNICATIONS

Assistant Commissioner
Vacant
(DAUB)

OFFICE OF
HEALTH AND CONSTITUENT AFFAIRS

Assistant Commissioner
Hia C. Marchand, Pharm.D.
(DAUC)

Legend:
- Direct report to
- General Counsel, HHS
- Indirect report to the
  Office of Chief Scientist
Illustrative Global Supply Chain for Canned Tuna

Products often traverse complex global supply chains to reach U.S. consumers.
Global Strategy

• Partner with foreign counterparts to create global coalitions of regulators focused on ensuring and improving global product safety.

• Work with these coalitions to build a global data-information system and network and proactively share data with peers.

• Expand capabilities in intelligence gathering and use, with an increased focus on risk analytics and modernized IT capabilities.

• Allocate agency resources effectively based on risk, leveraging the combined efforts of other government.
Global: FDA Foreign Offices
Globalization efforts

- Work to partner with foreign counterparts to create global coalitions of regulators.

- Member of Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme (PIC/S) since January of 2011
  - Annual sharing of surveillance inspections for the year

- Mutual Recognition Effort with EU

- Share specific information on planned inspections
  - Since October 1, 2014
    » Foreign regulators accompanied on 30 drug inspections
FDA’S OFFICE OF REGULATORY AFFAIRS ALIGNS FOR THE FUTURE

What

Why

How
“…Modernize and strengthen the FDA workforce to improve public health response.”

2013 FDA Program Alignment Charge
Geographically Aligned Organizational Model
Program Aligned Organizational Model

OFFICE OF THE ASSOCIATE COMMISSIONER FOR REGULATORY AFFAIRS

OFFICE OF MANAGEMENT

OFFICE OF COMMUNICATIONS AND PROJECT MANAGEMENT

OFFICE OF CRIMINAL INVESTIGATIONS

OFFICE OF HUMAN AND ANIMAL FOOD OPERATIONS

OFFICE OF MEDICAL PRODUCTS AND TOBACCO OPERATIONS

OFFICE OF REGULATORY SCIENCE

OFFICE OF PARTNERSHIPS AND OPERATIONAL POLICY

OFFICE OF ENFORCEMENT AND IMPORT OPERATIONS

OFFICE OF TRAINING, EDUCATION AND DEVELOPMENT
ORA at a Glance

Civil & Criminal Investigators
Import Operations
Compliance Officers
13 Laboratories
Emergency Response Coordinators
Recall Coordinators
Consumer Complaint Coordinators
Official Establishment Inventory Coordinators
Disclosure & FOIA

State Cooperative Programs—Milk, Retail, Shellfish
State Contracts, Grants & Agreements
State Liaisons
Quality Systems Managers
Planning & Evaluation Analysts
Operational Policy Analysts
Communications Staff
Administrative & Mission Support
Training, Education & Development Staff

Planning & Evaluation Analysts
Operational Policy Analysts
Communications Staff
Administrative & Mission Support
Training, Education & Development Staff

FDA
# Program Alignment: Key Changes

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geographic management of operations</td>
<td>Program management of operations, management teams based on staff:</td>
</tr>
<tr>
<td></td>
<td>• Bioresearch Monitoring</td>
</tr>
<tr>
<td></td>
<td>• Biologics</td>
</tr>
<tr>
<td></td>
<td>• Human and Animal Food</td>
</tr>
<tr>
<td></td>
<td>• Medical Device and Radiological Health</td>
</tr>
<tr>
<td></td>
<td>• Pharmaceutical Quality</td>
</tr>
<tr>
<td></td>
<td>• Tobacco</td>
</tr>
<tr>
<td></td>
<td>• Plus Imports as a program</td>
</tr>
<tr>
<td></td>
<td>2 management teams</td>
</tr>
<tr>
<td></td>
<td>2 management teams</td>
</tr>
<tr>
<td></td>
<td>12 management teams</td>
</tr>
<tr>
<td></td>
<td>3 management teams</td>
</tr>
<tr>
<td></td>
<td>4 management teams</td>
</tr>
<tr>
<td></td>
<td>5 management teams</td>
</tr>
<tr>
<td>SES Regional Food &amp; Drug Directors</td>
<td>SES Program Directors</td>
</tr>
<tr>
<td>Degrees of program specialization for investigations, compliance</td>
<td>Exclusive specialization in one program for investigations, compliance</td>
</tr>
<tr>
<td>and operational managers</td>
<td>and operational managers</td>
</tr>
<tr>
<td>20 District Directors who manage the geographic district and all</td>
<td>20 District Directors who manage the geographic district and only one</td>
</tr>
<tr>
<td>programs operations within the district</td>
<td>program for operations. Plus eight new program division directors who</td>
</tr>
<tr>
<td></td>
<td>manage program operations only – total 28 management teams</td>
</tr>
<tr>
<td>One import district and a range of import operations embedded within</td>
<td>Five import divisions (four new import divisions) covering all borders,</td>
</tr>
<tr>
<td>the 16 other districts</td>
<td>managing import operations nationally as a program</td>
</tr>
</tbody>
</table>
# Program Alignment: Key Changes

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 labs reporting into the regions</td>
<td>National Lab Management - 13 labs reporting into ORA’s Office of Regulatory Science with three additional directors managing separate program operations</td>
</tr>
<tr>
<td>Division of Human Resource Development within the Office of Resource Management</td>
<td>Office of Training, Education and Development</td>
</tr>
<tr>
<td>State Cooperative Programs decentralized across five regions – shellfish, milk, retail</td>
<td>Office of State Cooperative Programs under the Human and Animal Food Operations, as a single national program(s)</td>
</tr>
<tr>
<td>Functions based in geography: consumer complaint coordinators, state liaisons, emergency response coordinators</td>
<td>Retain certain functions based in geography: consumer complaint coordinators, state liaisons, emergency response coordinators</td>
</tr>
<tr>
<td>Functions decentralized local reporting: Freedom of Information (FOI) staff, industrial hygienists (IH), and administrative staff</td>
<td>Staff remain embedded locally, but report into a single office: FOI staff report into Division of Information Disclosure; IHs report into the Office of Regulatory Science; administrative staff report into the Office of Management</td>
</tr>
</tbody>
</table>
Offices of...

Melinda Plaisier, MSW
Associate Commissioner for Regulatory Affairs

Doug Stearn, JD
Director, Office of Enforcement and Import Operations

Paul Norris, DVM, MPA
Director, Office of Regulatory Science
Office of Enforcement and Import Operations

Doug Stearn, JD
Director, Office of Enforcement and Import Operations

DIVISION OF ENFORCEMENT

DIVISION OF FOOD DEFENSE TARGETING

DIVISION OF IMPORT OPERATIONS MANAGEMENT

DIVISION OF IMPORT PROGRAM DEVELOPMENT

DIVISION OF SOUTHWEST IMPORTS

DIVISION OF SOUTHEAST IMPORTS

DIVISION OF NORTHEAST IMPORTS

DIVISION OF NORTHERN BORDER IMPORTS

DIVISION OF WEST COAST IMPORTS
Office of Enforcement and Import Operations
Office of Regulatory Science

Lababoratory Type
- ORA Human and Animal Food Lab
- ORA Medical Products Lab
- ORA HAF & MPT (co-located)
- ORA Specialty Lab
- ORA Screening Station
- State Boundaries
Role of the Regulatory Laboratories

- Surveillance Testing
- Compliance (for cause) Testing
- Targeted surveys
- Provide technical assistance on inspections
- Regulatory method development

Mission Statement:

ORA’s laboratory network provides diverse scientific expertise, leadership, and responsive quality analytical services to safeguard public health in a global environment.
Chemistry

• Standard Testing includes:
  – Pesticides
  – Decomposition of Seafoods
  – Filth, Sanitation & Prohibited Materials in Regulated Products
  – Metals in Ceramic Ware
  – Herbal Products/Dietary Supplements
  – Chemotherapeutics in Seafood
  – Surgical Gloves & Condoms
  – Pharmaceuticals – Bulk ingredients/finished products
Microbiology

• Standard Testing includes:
  – *Salmonella*
  – *Listeria*
  – *Vibrio* species including toxigenic species
  – *Escherichia coli* O157:H7
  – *Staphylococcus* aureus and associated toxin
  – *Escherichia coli* and Coliforms
  – Alkaline Phosphatase (Cheese)
  – pH/Aw
Emergency Response

• Food Borne Outbreaks
  – Respond to *E. coli* O157:H7 (EHEC), *Listeria monocytogenes*, and *Salmonella*.
  – Bioterrorism Preparedness
    • Food Defense
    • BSL3 laboratory intentional contamination of food products.
    • In collaboration with the Food Emergency Response Network (FERN), Laboratory Response Network (LRN), Select Agent Program (CDC), and State Public Health Labs.
Laboratory Networks

- Food Emergency Response Network
- Laboratory Response Network
- National Animal Health Laboratory Network
- National Plant Diagnostic Network
- Environmental Network
Office of Biological Products Operations

OFFICE OF MEDICAL PRODUCTS AND TOBACCO OPERATIONS
OFFICE OF BIOLOGICAL PRODUCTS OPERATIONS

Ginette Michaud, MD
Director, Office of Biological Products Operations

DIVISION OF BIOLOGICAL PRODUCTS OPERATIONS I

DIVISION OF BIOLOGICAL PRODUCTS OPERATIONS II
Office of Biological Products Operations
Office of Bio research Monitoring Operations

Chrissy Cochran, PhD
Director, Office of Bio research Monitoring Operations
Office of Bioeresearch Monitoring Operations

BIMO Program Divisions
- Division 1 (ATL, BLT, CIN, FLA, NOL, NWE, NWJ, NYK, PHI, SJN)
- Division 2 (DAL, DEN, DET, KAN, CHI, LOS, MIN, SAN, SEA)

FDA Current
District Boundaries

Alaska - Division 2 (SEA)
Hawaii - Division 2 (SAN)
Puerto Rico - Division 1 (SJN)
Office of Medical Device and Radiological Health Operations

Jan Welch
Director, Office of Medical Device and Radiological Health

Office of Medical Products and Tobacco Operations
Office of Medical Devices and Radiological Health Operations

DIVISION OF MEDICAL DEVICES AND RADIOLOGICAL HEALTH OPERATIONS I
DIVISION OF MEDICAL DEVICES AND RADIOLOGICAL HEALTH OPERATIONS II
DIVISION OF MEDICAL DEVICES AND RADIOLOGICAL HEALTH OPERATIONS III
Office of Medical Device and Radiological Health Operations
Office of Pharmaceutical Quality Operations

Office of Medical Products and Tobacco Operations
Office of Pharmaceutical Quality Operations

Alonza Cruse
Director, Office of Pharmaceutical Quality Operations

Division of Pharmaceutical Quality Operations I
Division of Pharmaceutical Quality Operations II
Division of Pharmaceutical Quality Operations III
Division of Pharmaceutical Quality Operations IV
Division of Foreign Pharmaceutical Quality Programs
Division of Foreign Pharmaceutical Quality Inspections
Office of Human and Animal Food Operations

Michael Rogers, MS
Assistant Commissioner for Human and Animal Foods [acting]

Ellen Buchanan
Director, Audit Staff

Laurie Farmer
Director, Office of State Cooperative Programs [acting]

Vinetta Howard -King
Director, Office of Human and Animal Foods East [acting]

Joann Givens
Director, Office of Human and Animal Foods West
Office of Human and Animal Food Operations
ORA Ombudsman

- Informally and impartially addresses concerns, complaints, and disputes between ORA and external parties:
  - Industry
  - Federal, state, territory, and tribal government entities
  - Public

- Contact:
  - 513-679-2777 or 240-535-6021
  - ORAOmbudsman@fda.hhs.gov

Enhancing ORA operations by serving as an objective, neutral resource to improve communication channels, resolve disputes, and foster positive relationships with internal and external stakeholders.
The SVSP is one of several Federal Internships available in the Federal Government. Participants in the SVSP are unpaid volunteers.

This program is for students who are currently enrolled in an accredited educational institution seeking unpaid work experience or education-related training opportunities. Federal employee relatives may participate in SVSP consistent with the FDA policy on employment of relatives.

Volunteering at the FDA is limited to services performed by a student, with the permission of the educational institution where the student is enrolled. A written agreement between FDA and the educational institution must be established before we assign our volunteers.

https://www.fda.gov/aboutfda/workingatfda/fellowshipinternshipgraduatefacultyprograms/ucm530314.htm
In closing...

Between the FDA, Academia, Industry, National, International, Professional and Interest Group partners ...

... We do our best work when we work together!
Thank you for the opportunity to speak to you today!